Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Imatinib buys time for brain after stroke

Nature Medicine volume 14, pages 712–713 (2008)Cite this article

The most effective drug to treat acute ischemic stroke, tissue plasminogen activator (tPA), must be applied within three hours after symptom onset because of the risk of hemorrhage and other complications such as neurotoxicity. The anticancer drug imatinib (Gleevec) may help overcome these limitations by counteracting the ability of tPA to increase the permeability of the blood-brain barrier (pages 731–737).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Delayed tPA treatment in thrombembolic stroke.

Katie Ris-Vicari

References

  1. de la Ossa, N.P. et al. Neurology 70, 1238–1243 (2008).

    Article  Google Scholar 

  2. Kulkens, S. & Hacke, W. Expert Rev. Neurother. 7, 783–788 (2007).

    Article  Google Scholar 

  3. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N. Engl. J. Med. 333, 1581–1587 (1995).

  4. Tsirka, S.E. et al. J. Neurosci. 17, 543–552 (1997).

    Article  CAS  Google Scholar 

  5. Wang, Y.F. et al. Nat. Med. 4, 228–231 (1998).

    Article  CAS  Google Scholar 

  6. Zhuo, M. et al. J. Neurosci. 20, 542–549 (2000).

    Article  CAS  Google Scholar 

  7. Su, E.J. et al. Nat. Med. 14, 731–737 (2008).

    Article  CAS  Google Scholar 

  8. Fredriksson, L., Li, H., Fieber, C., Li, X. & Eriksson, U. EMBO J. 23, 3793–3802 (2004).

    Article  CAS  Google Scholar 

  9. Yepes, M. et al. J. Clin. Invest. 112, 1533–1540 (2003).

    Article  CAS  Google Scholar 

  10. Nicole, O. et al. Nat. Med. 7, 59–64 (2001).

    Article  CAS  Google Scholar 

  11. Breedveld, P., Beijnen, J.H. & Schellens, J.H. Trends Pharmacol. Sci. 27, 17–24 (2006).

    Article  CAS  Google Scholar 

  12. Krupinski, J. et al. Stroke 28, 564–573 (1997).

    Article  CAS  Google Scholar 

  13. Endres, M. et al. Cerebrovasc. Dis. 25, 268–278 (2008).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Peter Rieckmann is in the Division of Neurology, Brain Research Centre, University of British Columbia Hospital, 2211 Wesbrook Mall, Vancouver, British Columbia V6T 2B5, Canada. prieckmann@brain.ubc.ca,

    Peter Rieckmann

Authors
  1. Peter Rieckmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rieckmann, P. Imatinib buys time for brain after stroke. Nat Med 14, 712–713 (2008). https://doi.org/10.1038/nm0708-712

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0708-712

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing